Cabaletta up on FDA nod for trial on treatment for rare conditions

Cabaletta Bio

16/05/2023 16:55

(Updates)
    ** Shares of autoimmune disease therapy developer Cabaletta
Bio  CABA.O  rise 13.6% to $13.04
    ** Co says FDA has cleared its application to begin trial
for its therapy CABA-201
    ** CABA-201 is indicated for the treatment of a group of
rare conditions called Myositis
    ** Co plans to initiate trials for the treatment of six
patients with dermatomyositis, an uncommon inflammatory disease
marked by muscle weakness and a distinctive skin rash
    ** Co also plans to intiate trials with six patients with
autoimmune disease anti-synthetase syndrome and six patients
with immune-mediated necrotizing myopathy
    ** Stock up ~40% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))